Amylin receptor agonist targets Type 1 diabetes

Amylin Pharmaceuticals' pramlintide acetate (Symlin) is a synthetic version of amylin, the hormone secreted with insulin by the beta cells in the pancreas. It is the first member of a new class of medications known as amylinomimetic agents, or amylin receptor agonists. Amylinomimetic agents mimic the actions of amylin and have demonstrated activity in blood glucose regulation. The company recently submitted a complete response to the Food & Drug Administration's December 2003 approvable letter for pramlintide and is anticipating a six-month review.